They consider the employment of immune checkpoint inhibitors in head and neck cancer, such as pembrolizumab and nivolumab, both approved by the Food and Drug Administration (FDA).18-20 However, in oral cancer, the role of other components of the tumor microenvironment, such as inflammatory infiltrate, TILs, and CD4+ and CD8+ expression, remains to be better explored. This evidence concerns the gene CD4 and neoplasm.